SCHEMBL17021348

SCHEMBL17021348

CS(=O)(=O)Cc1ccc(Nc2cc(NCc3cccc(-c4ccncc4)c3)c(C(N)=O)nn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 5/20 0.48
▸ CDC7 O00311 2/20 0.44
▸ ROCK2 O75116 2/20 0.44
▸ MAP4K4 O95819 2/20 0.44
▸ GSK3B P49841 2/20 0.44
▸ CLK4 Q9HAZ1 2/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ CDK2 P24941 1/20 0.44
▸ MKNK2 Q9HBH9 1/20 0.43
▸ CSF1R P07333 3/20 0.42
▸ KDM4C Q9H3R0 1/20 0.41
▸ PRMT6 Q96LA8 1/20 0.39
▸ IRAK4 Q9NWZ3 2/20 0.39
▸ JAK2 O60674 2/20 0.39
▸ JAK1 P23458 2/20 0.39
▸ TYK2 P29597 2/20 0.39
▸ SYK P43405 3/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19010357 0.92 JAK3 (0.44) JAK3CDC7ROCK2MAP4K4GSK3B
SCHEMBL2695498 0.86 JAK3 (0.64) JAK3CDC7ROCK2MAP4K4GSK3B
SCHEMBL17021356 0.86 CDC7 (0.43) JAK3CDC7ROCK2MAP4K4GSK3B
SCHEMBL2694344 0.81 JAK3 (0.58) JAK3CDC7ROCK2MAP4K4GSK3B
SCHEMBL17021433 0.81 CD38 (0.41) JAK3CSF1RIRAK4JAK2JAK1
SCHEMBL17021300 0.80 JAK3 (0.52) JAK3CDC7ROCK2MAP4K4GSK3B
SCHEMBL17021435 0.79 AURKA (0.39) JAK3CSF1RIRAK4JAK2JAK1
SCHEMBL17021375 0.79 JAK3 (0.44) JAK3CDC7ROCK2MAP4K4GSK3B
SCHEMBL19010335 0.78 FFAR1 (0.41) JAK3CDC7ROCK2MAP4K4GSK3B
SCHEMBL2694014 0.77 JAK3 (0.61) JAK3CDC7ROCK2MAP4K4GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834548-B2 Pyridazine compounds as JAK inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-12-05 — — US disclosed
US-9834548-B2 Pyridazine compounds as JAK inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-12-05 — — US disclosed
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS ALEXION PHARMACEUTICALS, INC. 2017-06-22 — — US disclosed
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS ALEXION PHARMACEUTICALS, INC. 2017-06-22 — — US disclosed
WO-2015123453-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS JAK1, JAK2, JAK3 JAK3 3/4885CDC7 815/4885ROCK2 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback